Evidence map›Paper›PMID 38017028›Full record

ArticleNPJ vaccines2023

Author Correction: A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques.

Ting Bian, Meng Hao, Xiaofan Zhao, Chuanyi Zhao, Gang Luo, Zhendong Zhang, Guangcheng Fu, Lu Yang, Yi Chen, Yudong Wang and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ting BianLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.ORCID http://orcid.org/0009-0000-7505-8512
Meng HaoLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Xiaofan ZhaoLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Chuanyi ZhaoLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Gang LuoSchool of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, China.
Zhendong ZhangSchool of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, China.
Guangcheng FuLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Lu YangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Yi ChenLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Yudong WangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Changming YuLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China.
Yilong YangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China. yyl_pku@126.com.ORCID http://orcid.org/0000-0003-3412-0425
Jianmin LiLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China. lijmqz@126.com.ORCID http://orcid.org/0000-0002-2827-2185
Wei ChenLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, 100071, Beijing, China. cw0226@foxmail.com.ORCID http://orcid.org/0000-0001-5805-2469

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38017028
PMCPMC10684484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.